Humacyte, Inc. Common Stock

HUMANASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
1.08 USD
↘ 0.26 (19.40%)AT CLOSE (11:59 AM EDT)
1.05
↘ 0.03 (2.69%)
POST MARKET (AS OF 04:16 PM EDT)
Post Market
AS OF 04:16 PM EDT
1.05
↘ 0.03 (2.69%)
🟢Market: OPEN

Shares of Humacyte, Inc. Common Stock (HUMA) are trading at $1.09. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, HUMA trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 10, 2026.

Open?$1.05
High?$1.10
Low?$1.00
Prev. Close?$1.34
Volume?29.3M
Avg. Volume?7.0M
VWAP?$1.05
Rel. Volume?4.20x
Bid / Ask
Bid?$0.91 × 100
Ask?$1.25 × 100
Spread?$0.34
Midpoint?$1.08
Valuation & Ratios
Market Cap?297.5M
Shares Out?222.0M
Float?196.5M
Float %?88.5%
P/E Ratio?N/A
P/B Ratio?25.59
EPS?-$0.44
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Themes
Biotech - Drug Development›Clinical-Stage Platforms
Employees
184
Market Cap
297.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.humacyte.com
Listed
2021-08-27
Address
2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM, NC 27713
Phone: 919-313-9633
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
50
Short Sent.?
45
Piotroski F-Score?1/9Weak
Altman Z-Score?-10.49Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.42%Squeeze Risk
Short Interest?40.1M
Days to Cover?6.1
Free Float196.5M
Avg Daily Volume6.5M
Settlement Date2026-05-29
Financial Health
Current Ratio?3.93Strong
Quick Ratio?3.32Strong
Cash Ratio?3.00Strong
Debt/Equity?5.67High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
25.59HIGH▾
P/S?
Peers
100
S&P
3
147.57HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
156.18HIGH▾
Returns & Efficiency
ROE?
S&P
3
-839.6%WEAK▾
ROA?
S&P
3
-88.3%WEAK▾
Cash Flow & Enterprise
FCF?$-102376000
Enterprise Value?$314.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist